JP2025041652A5 - - Google Patents

Info

Publication number
JP2025041652A5
JP2025041652A5 JP2024209791A JP2024209791A JP2025041652A5 JP 2025041652 A5 JP2025041652 A5 JP 2025041652A5 JP 2024209791 A JP2024209791 A JP 2024209791A JP 2024209791 A JP2024209791 A JP 2024209791A JP 2025041652 A5 JP2025041652 A5 JP 2025041652A5
Authority
JP
Japan
Prior art keywords
sfg
sfu
sfa
composition
modified nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024209791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025041652A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/027109 external-priority patent/WO2019200185A1/en
Priority claimed from PCT/US2019/031672 external-priority patent/WO2019217784A1/en
Priority claimed from JP2021531966A external-priority patent/JP2022513719A/ja
Application filed filed Critical
Publication of JP2025041652A publication Critical patent/JP2025041652A/ja
Publication of JP2025041652A5 publication Critical patent/JP2025041652A5/ja
Pending legal-status Critical Current

Links

JP2024209791A 2018-12-06 2024-12-02 オリゴヌクレオチド組成物及びその方法 Pending JP2025041652A (ja)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201862776432P 2018-12-06 2018-12-06
US62/776,432 2018-12-06
PCT/US2019/027109 WO2019200185A1 (en) 2018-04-12 2019-04-11 Oligonucleotide compositions and methods of use thereof
USPCT/US2019/027109 2019-04-11
PCT/US2019/031672 WO2019217784A1 (en) 2018-05-11 2019-05-10 Oligonucleotide compositions and methods of use thereof
USPCT/US2019/031672 2019-05-10
US201962916192P 2019-10-16 2019-10-16
US201962916194P 2019-10-16 2019-10-16
US62/916,192 2019-10-16
US62/916,194 2019-10-16
JP2021531966A JP2022513719A (ja) 2018-12-06 2019-12-06 オリゴヌクレオチド組成物及びその方法
PCT/US2019/065058 WO2020118246A1 (en) 2018-12-06 2019-12-06 Oligonucleotide compositions and methods thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021531966A Division JP2022513719A (ja) 2018-12-06 2019-12-06 オリゴヌクレオチド組成物及びその方法

Publications (2)

Publication Number Publication Date
JP2025041652A JP2025041652A (ja) 2025-03-26
JP2025041652A5 true JP2025041652A5 (enExample) 2025-10-17

Family

ID=70973999

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531966A Ceased JP2022513719A (ja) 2018-12-06 2019-12-06 オリゴヌクレオチド組成物及びその方法
JP2024209791A Pending JP2025041652A (ja) 2018-12-06 2024-12-02 オリゴヌクレオチド組成物及びその方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021531966A Ceased JP2022513719A (ja) 2018-12-06 2019-12-06 オリゴヌクレオチド組成物及びその方法

Country Status (8)

Country Link
US (1) US20220186217A1 (enExample)
EP (1) EP3891284A4 (enExample)
JP (2) JP2022513719A (enExample)
CN (1) CN113383078A (enExample)
AU (1) AU2019392928A1 (enExample)
CA (1) CA3122271A1 (enExample)
SG (1) SG11202105626TA (enExample)
WO (1) WO2020118246A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112007045A (zh) 2012-07-13 2020-12-01 波涛生命科学有限公司 手性控制
ES2862073T3 (es) 2012-07-13 2021-10-06 Wave Life Sciences Ltd Grupo auxiliar asimétrico
CN113278617A (zh) 2014-01-16 2021-08-20 波涛生命科学有限公司 手性设计
RU2708237C2 (ru) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US11407775B2 (en) 2016-03-13 2022-08-09 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
MA45188A (fr) 2016-06-03 2019-04-10 Wave Life Sciences Ltd Oligonucléotides, compositions et méthodes associées
CN109477103A (zh) 2016-06-22 2019-03-15 ProQR治疗上市公司Ⅱ 单链rna-编辑寡核苷酸
ES2837076T3 (es) 2016-09-01 2021-06-29 Proqr Therapeutics Ii Bv Oligonucleótidos para la edición de ARN de cadena sencilla modificados químicamente
MA46905A (fr) 2016-11-23 2019-10-02 Wave Life Sciences Ltd Compositions et procédés de synthèse de phosphoramidites et d'oligonucléotides
JP7557941B2 (ja) 2017-06-02 2024-09-30 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物及びその使用方法
WO2018223056A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
CN110996968A (zh) 2017-08-08 2020-04-10 波涛生命科学有限公司 寡核苷酸组合物及其方法
KR20200052369A (ko) 2017-09-18 2020-05-14 웨이브 라이프 사이언시스 리미티드 올리고뉴클레오티드 제조 기술
WO2019075357A1 (en) 2017-10-12 2019-04-18 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
AU2019265904A1 (en) 2018-05-11 2020-11-12 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
CN113748116A (zh) * 2019-03-20 2021-12-03 波涛生命科学有限公司 可用于寡核苷酸制备的技术
CA3159944A1 (en) 2019-12-02 2021-06-10 David HUSS Therapeutic editing
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US20250154190A1 (en) * 2022-02-11 2025-05-15 Wave Life Sciences Ltd. Stereoselective technologies for chiral compounds
WO2023152371A1 (en) 2022-02-14 2023-08-17 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
EP4555085A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Chemically modified oligonucleotides for adar-mediated rna editing
WO2024013361A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Oligonucleotides for adar-mediated rna editing and use thereof
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
KR20250113455A (ko) 2022-11-24 2025-07-25 프로큐알 테라퓨틱스 Ⅱ 비.브이. 유전성 hfe-혈색소침착증의 치료를 위한 안티센스 올리고뉴클레오티드
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
KR20250115388A (ko) 2022-12-09 2025-07-30 프로큐알 테라퓨틱스 Ⅱ 비.브이. 심혈관 질환 치료용 안티센스 올리고뉴클레오타이드
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
CN121039282A (zh) 2023-03-24 2025-11-28 ProQR治疗上市公司Ⅱ 用于治疗神经系统病症的反义寡核苷酸
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
AU2024246572A1 (en) 2023-03-27 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
TW202516003A (zh) 2023-06-16 2025-04-16 荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ 用於治療神經退化性疾病之反義寡核苷酸
WO2025051946A1 (en) 2023-09-07 2025-03-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2025072881A2 (en) * 2023-09-28 2025-04-03 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2025072879A1 (en) * 2023-09-28 2025-04-03 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2025104239A1 (en) 2023-11-16 2025-05-22 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
WO2025132708A1 (en) 2023-12-20 2025-06-26 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
WO2025213142A2 (en) * 2024-04-05 2025-10-09 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617442B1 (en) * 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
AU2002362312A1 (en) * 2001-09-17 2003-04-01 Mayo Foundation For Medical Education And Research Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
CN101896186A (zh) * 2007-10-26 2010-11-24 莱顿教学医院 对抗肌肉病症的方式和方法
DK2607484T3 (en) * 2008-10-27 2016-03-07 Biomarin Technologies B V Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-MRNA
WO2011109427A2 (en) * 2010-03-01 2011-09-09 Alnylam Pharmaceuticals, Inc. Improving the biological activity of sirna through modulation of its thermodynamic profile
CN112007045A (zh) * 2012-07-13 2020-12-01 波涛生命科学有限公司 手性控制
CN113278617A (zh) * 2014-01-16 2021-08-20 波涛生命科学有限公司 手性设计
SG11201607095RA (en) * 2014-03-12 2016-10-28 Nippon Shinyaku Co Ltd Antisense nucleic acids
RU2708237C2 (ru) * 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
EP3359668A4 (en) * 2015-10-09 2019-06-05 Sarepta Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATING DUCHENNE MUSCLE DYSTROPHY AND ASSOCIATED ILLNESSES THEREOF
NZ781029A (en) * 2015-10-09 2025-07-25 Wave Life Sciences Ltd Oligonucleotide compositions and methods thereof
KR102824513B1 (ko) * 2016-07-05 2025-06-25 바이오마린 테크놀로지스 비.브이. 유전적 장애 치료를 위한, 특징이 개선된, 비사이클릭 스캐폴드 모이어티를 포함하는 프리-mrna 스플라이스 스위칭 또는 조정 올리고뉴클레오티드

Similar Documents

Publication Publication Date Title
JP2025041652A5 (enExample)
JPWO2019217784A5 (enExample)
JPWO2020118246A5 (enExample)
JP2023145620A5 (enExample)
JP2024056718A5 (enExample)
JPWO2021071858A5 (enExample)
Agrawal et al. Modified oligonucleotides as therapeutic and diagnostic agents
JP2024099745A5 (enExample)
JP2021074021A5 (enExample)
JP2020522265A5 (enExample)
JP2023078293A5 (enExample)
JPWO2021071788A5 (enExample)
JP2018525357A5 (enExample)
JP2020524485A5 (enExample)
JPWO2022270585A5 (enExample)
JPWO2022099159A5 (enExample)
JPWO2020227691A5 (enExample)
JPWO2021178237A5 (enExample)
JP5995855B2 (ja) 塩基修飾オリゴヌクレオチド
JP2019525918A5 (enExample)
JP2017525705A5 (enExample)
FI4426269T3 (fi) Lipidinanopartikkelit oligonukleotidien antamiseksi
AU2018332216A1 (en) Galnac derivatives
JP2005525991A5 (enExample)
FI4426270T3 (fi) Lipidi-nanopartikkelit oligonukleotidien kuljetusta varten